Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

ABSTRACT:

SUBMITTER: Motzer RJ 

PROVIDER: S-EPMC7497870 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature